RBC Capital analyst Ben Hendrix raised the firm’s price target on HCA Healthcare to $283 from $239 and keeps an Outperform rating on the shares. The company’s Q4 results were "solid" and its initial 2023 guidance reflects a core EBITDA growth assumption that is near the midpoint of historical ranges, the analyst tells investors in a research note. The firm is also adjusting the target enterprise value to expected EBITDA multiple in its model to 9.5-times from 9.0-times given HCA’s continued strong demand, along with its focus on capacity and cost management initiatives.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HCA:
- HCA Healthcare price target raised to $290 from $270 at Truist
- HCA Healthcare price target raised to $292 from $238 at Cowen
- HCA Healthcare price target raised to $279 from $265 at Mizuho
- HCA Healthcare price target raised to $293 from $280 at Citi
- HCA Healthcare sees FY23 EPS $16.40-$17.60, consensus $18.23
